Biomarker & Intervention Discovery

GERD (Gastroesophageal Reflux Disease)

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Research Tracker / Chronic Disease Interventions / GERD (Gastroesophageal Reflux Disease) / Biomarker Atlas →

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
—
Gap size
—
Primary barrier
—
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ATP4A 226CHRM3 280CLDN1 0HRH2 218IL8 152PTGS2 299TJP1 4TRPV1 160

ATP4A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIFEDIPINE ↑ activates Mechanistic DGIdb
EPIPREGNANOLONE SULPHATE ↑ activates Mechanistic DGIdb
ESOMEPRAZOLE MAGNESIUM TRIHYDRATE ↓ inhibits Mechanistic DGIdb
PIOGLITAZONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
HALOTHANE ↓ inhibits Mechanistic DGIdb
NN-DIMETHYL-D-ERYTHROSPHINGOSINE ↑ activates Mechanistic DGIdb
NA+ ↓ inhibits Mechanistic DGIdb
PREGNENOLONE SULPHATE ↑ activates Mechanistic DGIdb
(S)-LIQUIRITIGENIN ↓ inhibits Mechanistic DGIdb
ILAPRAZOLE ↓ inhibits Mechanistic DGIdb
CIM0216 ↑ activates Mechanistic DGIdb
NARINGENIN ↓ inhibits Mechanistic DGIdb
MAPROTILINE ↓ inhibits Mechanistic DGIdb
TEGOPRAZAN ↓ inhibits Mechanistic DGIdb
LA3+ ↓ inhibits Mechanistic DGIdb
ISOSAKURANETIN ↓ inhibits Mechanistic DGIdb
TROGLITAZONE ↓ inhibits Mechanistic DGIdb
SPHINGOSINE ↑ activates Mechanistic DGIdb
FEXUPRAZAN ↓ inhibits Mechanistic DGIdb
PENTAFLUORO-TRITYL CLOTRIMAZOLE ANALOGUE 29A ↑ activates Mechanistic DGIdb
GD3+ ↓ inhibits Mechanistic DGIdb
ROSIGLITAZONE ↓ inhibits Mechanistic DGIdb
DIHYDROSPHINGOSINE ↑ activates Mechanistic DGIdb
PRIMIDONE ↓ inhibits Mechanistic DGIdb
2-APB ↓ inhibits Mechanistic DGIdb
OMEPRAZOLE MAGNESIUM ↓ inhibits Mechanistic DGIdb
CHLOROFORM ↓ inhibits Mechanistic DGIdb
MEFENAMIC ACID ↓ inhibits Mechanistic DGIdb
PANTOPRAZOLE SODIUM ↓ inhibits Mechanistic DGIdb
VONOPRAZAN FUMARATE ↓ inhibits Mechanistic DGIdb
RABEPRAZOLE ↓ inhibits Mechanistic DGIdb
OMEPRAZOLE ↓ inhibits Mechanistic 3800.0 nM (IC50) DGIdb
ESOMEPRAZOLE SODIUM ↓ inhibits Mechanistic DGIdb
LANSOPRAZOLE ↓ inhibits Mechanistic 398.11 nM (IC50) DGIdb
ESOMEPRAZOLE STRONTIUM ↓ inhibits Mechanistic DGIdb
DICLOFENAC SODIUM ↓ inhibits Mechanistic DGIdb
ABEPRAZAN ? unclear Mechanistic Open Targets
ESOMEPRAZOLE MAGNESIUM ? unclear Mechanistic Open Targets
RABEPRAZOLE SODIUM ? unclear Mechanistic Open Targets
DEXLANSOPRAZOLE ? unclear Mechanistic Open Targets

Showing top 40 of 226 agents ranked by evidence tier.

CHRM3

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TARAFENACIN ? unclear Mechanistic DGIdb
METHIXENE ? unclear Mechanistic DGIdb
OXYBUTYNIN ↓ inhibits Mechanistic DGIdb
CEVIMELINE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
ZAMIFENACIN ? unclear Mechanistic DGIdb
IMIDAFENACIN ↓ inhibits Mechanistic DGIdb
TIOTROPIUM ? unclear Mechanistic DGIdb
BENZQUINAMIDE ? unclear Mechanistic DGIdb
TOLTERODINE ↓ inhibits Mechanistic DGIdb
OCTOTROPINE METHYLBROMIDE ↓ inhibits Mechanistic DGIdb
SOLIFENACIN ? unclear Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL1084941 ? unclear Mechanistic DGIdb
IPRATROPIUM CATION ↓ inhibits Mechanistic DGIdb
PROMAZINE ? unclear Mechanistic DGIdb
CLIDINIUM ↓ inhibits Mechanistic DGIdb
BATEFENTEROL ↓ inhibits Mechanistic DGIdb
BETHANECHOL CHLORIDE ↑ activates Mechanistic DGIdb
OLANZAPINE ? unclear Mechanistic DGIdb
OXYPHENCYCLIMINE ? unclear Mechanistic DGIdb
TRIDIHEXETHYL ? unclear Mechanistic DGIdb
ACETYLCHOLINE CHLORIDE ↑ activates Mechanistic DGIdb
METHACHOLINE CHLORIDE ↑ activates Mechanistic DGIdb
TRIDIHEXETHYL CHLORIDE ↓ inhibits Mechanistic DGIdb
CYCLOPENTOLATE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
REVEFENACIN ↓ inhibits Mechanistic DGIdb
PIPERTRAMINE ? unclear Mechanistic DGIdb
FESOTERODINE ↓ inhibits Mechanistic DGIdb
CCG-50014 ? unclear Mechanistic DGIdb
ATROPINE SULFATE ↓ inhibits Mechanistic DGIdb
PROMETHAZINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
ACLIDINIUM BROMIDE ↓ inhibits Mechanistic DGIdb
TROPICAMIDE ↓ inhibits Mechanistic DGIdb
DAROTROPIUM BROMIDE ↓ inhibits Mechanistic DGIdb
ACECLIDINE ? unclear Mechanistic DGIdb
SOLIFENACIN SUCCINATE ↓ inhibits Mechanistic DGIdb
DEXAMETHASONE ? unclear Mechanistic DGIdb
TIOTROPIUM BROMIDE ↓ inhibits Mechanistic DGIdb
TROSPIUM ↓ inhibits Mechanistic DGIdb
GLYCOPYRRONIUM ↓ inhibits Mechanistic DGIdb

Showing top 40 of 280 agents ranked by evidence tier.

CLDN1

UniProt Ensembl DGIdb Open Targets

Pipeline results not yet available for this target. Run the pipeline to populate.

HRH2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NIZATIDINE ↓ inhibits Mechanistic DGIdb
FAMOTIDINE ↓ inhibits Mechanistic DGIdb
RANITIDINE BISMUTH CITRATE ↓ inhibits Mechanistic DGIdb
BETAZOLE ? unclear Mechanistic DGIdb
MS31 ↓ inhibits Mechanistic DGIdb
RANITIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
BETAZOLE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
EPINASTINE ? unclear Mechanistic DGIdb
LAFUTIDINE ↓ inhibits Mechanistic DGIdb
HISTAMINE ? unclear Mechanistic 463.0 nM (EC50) DGIdb
TOLAZOLINE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
CIMETIDINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
EBROTIDINE ↓ inhibits Mechanistic DGIdb
DOXEPIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
METHANTHELINE BROMIDE ↓ inhibits Mechanistic DGIdb
ASENAPINE ? unclear Mechanistic DGIdb
CIMETIDINE ↓ inhibits Mechanistic DGIdb
MS8535 ↓ inhibits Mechanistic DGIdb
TOLAZOLINE ? unclear Mechanistic Open Targets
METHANTHELINE ? unclear Mechanistic Open Targets
RANITIDINE ? unclear Mechanistic Open Targets
VUF-5297 ↑ activates Mechanistic 696.0 nM (EC50) ChEMBL
CHEMBL72424 ↓ inhibits Mechanistic 10000.0 nM (Ki) ChEMBL
CHEMBL70603 ↓ inhibits Mechanistic 10000.0 nM (Ki) ChEMBL
CHEMBL44220 ↓ inhibits Mechanistic 19952.62 nM (Ki) ChEMBL
CHEMBL72571 ↓ inhibits Mechanistic 3981.07 nM (Ki) ChEMBL
CHEMBL310087 ↓ inhibits Mechanistic 12589.25 nM (Ki) ChEMBL
CHEMBL70811 ↓ inhibits Mechanistic 1584.89 nM (Ki) ChEMBL
CHEMBL72372 ↓ inhibits Mechanistic 1584.89 nM (Ki) ChEMBL
CHEMBL418470 ↑ activates Mechanistic 93.0 nM (EC50) ChEMBL
CHEMBL308717 ↓ inhibits Mechanistic 5011.87 nM (Ki) ChEMBL
BURIMAMIDE ↓ inhibits Mechanistic 3981.07 nM (Ki) ChEMBL
VUF-5296 ↑ activates Mechanistic 2500.0 nM (EC50) ChEMBL
CHEMBL305929 ↓ inhibits Mechanistic 3162.28 nM (Ki) ChEMBL
CHEMBL104994 ↓ inhibits Mechanistic 22000.0 nM (Ki) ChEMBL
CHEMBL107293 ↓ inhibits Mechanistic 380.0 nM (Ki) ChEMBL
CHEMBL102840 ↓ inhibits Mechanistic 2300.0 nM (Ki) ChEMBL
CHEMBL104808 ↓ inhibits Mechanistic 500.0 nM (Ki) ChEMBL
CHEMBL105071 ↓ inhibits Mechanistic 730.0 nM (Ki) ChEMBL
CHEMBL101634 ↓ inhibits Mechanistic 6200.0 nM (Ki) ChEMBL

Showing top 40 of 218 agents ranked by evidence tier.

IL8

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
VITAMIN A ? unclear Mechanistic DGIdb
FENTANYL CITRATE ? unclear Mechanistic DGIdb
ALPRAZOLAM ? unclear Mechanistic DGIdb
FENRETINIDE ? unclear Mechanistic DGIdb
RIBAVIRIN ? unclear Mechanistic DGIdb
RECOMBINANT INTERLEUKIN-1 ? unclear Mechanistic DGIdb
CIDOFOVIR ANHYDROUS ? unclear Mechanistic DGIdb
DIPYRIDAMOLE ? unclear Mechanistic DGIdb
TROGLITAZONE ? unclear Mechanistic DGIdb
LANSOPRAZOLE ? unclear Mechanistic DGIdb
IONOMYCIN ? unclear Mechanistic DGIdb
E319 ? unclear Mechanistic DGIdb
CEFTRIAXONE ? unclear Mechanistic DGIdb
CHLORDANE ? unclear Mechanistic DGIdb
FOSCARNET ? unclear Mechanistic DGIdb
ADAKITUG ↓ inhibits Mechanistic DGIdb
DANAZOL ? unclear Mechanistic DGIdb
D-ALPHA-TOCOPHEROL ACETATE ? unclear Mechanistic DGIdb
DICYCLOHEXYLCARBODIIMIDE ? unclear Mechanistic DGIdb
RO 31-8220 ? unclear Mechanistic DGIdb
BEVACIZUMAB ? unclear Mechanistic DGIdb
BROXURIDINE ? unclear Mechanistic DGIdb
TRETINOIN ? unclear Mechanistic DGIdb
ALL-TRANS-RETINAL ? unclear Mechanistic DGIdb
METHIMAZOLE ? unclear Mechanistic DGIdb
DEOXYSPERGUALIN ? unclear Mechanistic DGIdb
PAZOPANIB ? unclear Mechanistic DGIdb
OMEPRAZOLE ? unclear Mechanistic DGIdb
ALPHA-TOCOPHEROL ACETATE ? unclear Mechanistic DGIdb
MEDROXYPROGESTERONE ACETATE ? unclear Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
TETRADECANOYLPHORBOL ACETATE ? unclear Mechanistic DGIdb
PENTOXIFYLLINE ? unclear Mechanistic DGIdb
PYROGALLOL ? unclear Mechanistic DGIdb
KLEBSIELLA PNEUMONIAE GLYCOPROTEIN ? unclear Mechanistic DGIdb
ABX-IL8 ↓ inhibits Mechanistic DGIdb
FLUOROURACIL ? unclear Mechanistic DGIdb
BIOFLAVONOID ? unclear Mechanistic DGIdb
LEFLUNOMIDE ? unclear Mechanistic DGIdb
QUESTIOMYCIN B ? unclear Mechanistic DGIdb

Showing top 40 of 152 agents ranked by evidence tier.

PTGS2

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CARPROFEN ↓ inhibits Mechanistic 102.0 nM (IC50) DGIdb
INDOMETHACIN SODIUM ↓ inhibits Mechanistic DGIdb
DARBUFELONE ? unclear Mechanistic DGIdb
MEFENAMIC ACID ↓ inhibits Mechanistic DGIdb
MECLOFENAMATE SODIUM ↓ inhibits Mechanistic DGIdb
DICLOFENAC SODIUM ↓ inhibits Mechanistic DGIdb
CAPECITABINE ? unclear Mechanistic DGIdb
PIRPROFEN ↓ inhibits Mechanistic DGIdb
ESFLURBIPROFEN ↓ inhibits Mechanistic DGIdb
SULFASALAZINE ↓ inhibits Mechanistic DGIdb
BROMFENAC ? unclear Mechanistic DGIdb
IBUPROFEN, SODIUM SALT ↓ inhibits Mechanistic DGIdb
ALOXIPRIN ↓ inhibits Mechanistic DGIdb
TENOXICAM ? unclear Mechanistic DGIdb
FLURBIPROFEN ↓ inhibits Mechanistic DGIdb
SALICYLIC ACID ? unclear Mechanistic DGIdb
ATENOLOL ? unclear Mechanistic DGIdb
DEXKETOPROFEN ↓ inhibits Mechanistic DGIdb
ETORICOXIB ↓ inhibits Mechanistic DGIdb
LUMIRACOXIB ↓ inhibits Mechanistic DGIdb
SUPROFEN ↓ inhibits Mechanistic DGIdb
NS-398 ? unclear Mechanistic DGIdb
NABUMETONE ↓ inhibits Mechanistic DGIdb
URSOLIC ACID ? unclear Mechanistic DGIdb
IBUPROFEN LYSINE ↓ inhibits Mechanistic DGIdb
ACECLOFENAC ↓ inhibits Mechanistic DGIdb
IBUFENAC ↓ inhibits Mechanistic DGIdb
BALSALAZIDE ? unclear Mechanistic DGIdb
DIFLUNISAL ↓ inhibits Mechanistic DGIdb
BALSALAZIDE DISODIUM ↓ inhibits Mechanistic DGIdb
VACCINE ? unclear Mechanistic DGIdb
KETOROLAC TROMETHAMINE ↓ inhibits Mechanistic DGIdb
BENZYDAMINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TIAPROFENIC ACID ? unclear Mechanistic DGIdb
RALOXIFENE HYDROCHLORIDE ? unclear Mechanistic DGIdb
NAPROXCINOD ↓ inhibits Mechanistic DGIdb
IGURATIMOD ↓ inhibits Mechanistic DGIdb
ETODOLAC ↓ inhibits Mechanistic DGIdb
DICLOFENAC ETALHYALURONATE SODIUM ↓ inhibits Mechanistic DGIdb
ROFECOXIB ↓ inhibits Mechanistic 530.0 nM (IC50) DGIdb

Showing top 40 of 299 agents ranked by evidence tier.

TJP1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
DEXAMETHASONE ? unclear Mechanistic DGIdb
RISPERIDONE ? unclear Mechanistic DGIdb
DEHYDRATED ALCOHOL ? unclear Mechanistic DGIdb
GENISTEIN ? unclear Mechanistic DGIdb

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
STREPTOZOCIN ? unclear Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
SAF312 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
TIVANISIRAN ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
PHENETHYLISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
RESINIFERATOXIN ↑ activates Mechanistic 23.1 nM (Ki) DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
XEN-D0501 ↓ inhibits Mechanistic DGIdb
PAC-14028 ↓ inhibits Mechanistic DGIdb
SB-705498 ↓ inhibits Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
ALLYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
NGD-8243 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
RESERPINE ? unclear Mechanistic DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
A425619 ? unclear Mechanistic DGIdb
PHE377 ↓ inhibits Mechanistic DGIdb
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic DGIdb
WORTMANNIN ? unclear Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ? unclear Mechanistic 120.0 nM (Ki) DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
CHEMBL:CHEMBL191534 ? unclear Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb

Showing top 40 of 160 agents ranked by evidence tier.

Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-02.

Evaluation of the Fundoplicature of the Excluded Stomach Post Omega Bypass Recruiting
NCT06621979 Phase: NA Started: 2025-11-24

The purpose of this study is to evaluate the efficacy of fundoplication with stomach excluded in the suppression of disabling gastroesophageal reflux requiring surgery in patients who have undergone one anastomosis gastric bypass, with complete objective evaluation of reflux.

An Observational Study to Evaluate the Efficacy and Safety of K-CAB Tab./K-CAB ODT(Tegoprazan) in GERD Patients Recruiting
NCT07678177 Phase: N/A Started: 2023-03-07

This study aims to evaluate the status of AE and improvement effect of K-CAB Tab/K-CAB ODT(Tegoprazan) 50mg in patients with GERD.

A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole Completed
NCT05055128 Phase: PHASE2 Started: 2021-08-11

This study will be conducted in patients with erosive esophagitis due to gastro-esophageal reflux disease (GERD) Los Angeles (LA) grades C or D, and in patients with at least partial symptom response but still endoscopically unhealed (LA grades A or B) after 8 weeks history of standard treatment hea...

Redo Surgery or Transcatheter Valve-in-Valve for Mitral Bioprosthetic Dysfunction (SURViV) Completed
NCT04402931 Phase: NA Started: 2020-02-17

Transcatheter valve-in-valve implantation has emerged as a valid alternative to redo surgery for patients with surgical bioprosthetic dysfunction. Nowadays, transcatheter, transeptal mitral valve-in-valve replacement (TsMViV) has been adopted in many centers worldwide. Some studies report low rates ...

Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia Recruiting
NCT06534359 Phase: NA Started: 2025-07-15

The goal of this clinical trial is to learn if transpyloric tube feeding (feeding directly into the small intestine) versus gastric tube feeding tolerably and effectively reduces gastroesophageal reflux in infants born premature who have been diagnosed with bronchopulmonary dysplasia. The main quest...

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants Recruiting
NCT05777512 Phase: NA Started: 2024-04-26

The purpose of this study is to determine if postpyloric feedings effectively improve objective measures of pulmonary health in preterm infants with chronic lung disease when compared with nasogastric (NG) feedings. This research will (1) determine the optimal nutritional management to prevent a com...

Esophagogastric Junction Distensibility During Hiatal Hernia Repair Active Not Recruiting
NCT04450628 Phase: NA Started: 2020-09-28

The investigators aim to ascertain the effects of hiatal hernia repair and fundoplication on the distensibility of the esophagogastric junction (EGJ) as measured by FLIP topography/impedance planimetry. The investigators also aim to assess for any correlation between values of EGJ distensibility and...

Safety and Effectiveness of eGERD Device to Reduce Gastroesophageal Reflux Disease (GERD) Symptoms Recruiting
NCT06613438 Phase: NA Started: 2024-09-15

The purpose of this research is to evaluate the safety and effectiveness of the eGERD device, which is a novel device for treating Gastroesophageal Reflux Disease (GERD). The main questions this research aims to answer are: 1. Does the eGERD device reduce acidity in the esophagus? 2. Does the eGER...

Abbott Cephea Mitral Valve Disease Registry Recruiting
NCT07069673 Phase: N/A Started: 2025-08-13

The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of cor...

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study Completed
NCT03105375 Phase: EARLY_PHASE1 Started: 2017-02-21

The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.

Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus Active Not Recruiting
NCT00431756 Phase: N/A Started: 2002-05-01

The purpose of this study is to determine if there are any early changes in DNA markers of blood and esophageal tissue in people with gastric reflux, Barrett's esophagus or esophageal cancer that can warn of a progression to esophageal cancer.

The Detection of Barrett's Esophagus by Gastrointestinal Endoscopy Prevents Esophageal Carcinoma in Morbid Obese After Sleeve Gastrectomy Completed
NCT03596411 Phase: N/A Started: 2018-05-17

Severe Gastroesophageal reflux disease (GERD) leading to a chronic aggression of esophagus mucosa, called Barrett's esophagus is a main complication of Sleeve gastrectomy for morbid obesity. Barrett's esophagus is considered as a early stage of neoplastic transformation to adenocarcinoma. Since this...

Evaluating Medication Adherence of Patients With Gastroesophageal Reflux Disease With Support of the Smartphone Application GERDCare Recruiting
NCT07125521 Phase: NA Started: 2025-08-18

Adherence to GERD treatment, including medication, diet, and lifestyle, is essential for symptom control and complication prevention, yet adherence rates remain low due to various demographic and clinical factors. Digital therapeutics, particularly mobile health applications, have shown promising po...

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy Active Not Recruiting
NCT03705416 Phase: N/A Started: 2019-03-30

GERD is common in the obese population. Bariatric procedures are the mainstay of therapy for these patients. Bariatric procedures can be surgical (Roux-en-Y gastric bypass and Vertical sleeve gastrectomy) or endoscopic (endoscopic sleeve gastroplasty). The rate of GERD after either treatment is unkn...

A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate Recruiting
NCT05469854 Phase: PHASE1 Started: 2022-07-13

This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linapra...

Agents Found By Disease-Level Search

Searched directly from “GERD (Gastroesophageal Reflux Disease)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

60 agents shown (approved or with trial evidence) — 54 not found by the gene-target search above.

Esomeprazole

Approved · 4 trials · source: ClinicalTrials.gov, Open Targets
NCT04329000 NCT00317044 NCT00317044

pantoprazole

Approved · 3 trials · source: ClinicalTrials.gov, Open Targets
NCT00362609 NCT00307944 NCT01887743

Lansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01990339 NCT01135368

Vonoprazan

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT05366738 NCT05366738

Dexlansoprazole

Approved · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT02616302 NCT00627016

Esomeprazole 40 mgNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT04568772 NCT04329000

AZD3355NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00757419

EG Scan II (transnasal endoscopy)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Standard EndoscopyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02066233

Lap Nissen fundoplication with division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Laparoscopic Nissen fundoplication without division of short gastric vesselsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00852098

Standard dose (once daily) PPI plus low-dose antidepressantNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Double dose PPI plus evening placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

Rabeprazole , placebo, placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251732

gastroenteroanastomosis simultaneous to vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

vertical sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07537244

NortriptylineNOT in gene-target list

Phase 2/3 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT01065649

Placebo armNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01065649

Thickened infant formulaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02710955

Medtronic Intrepid™ TMVR TF SystemNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05496998

Dexrabeprazole 10 mg Enteric-Coated TabletsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02689999

Omeprazole

Approved · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00256737

High-Resolution Manometry, Upper-GI endoscopy, pH-Impedance testingNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06151067

AciphexNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00204698

DIMAC02NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02789800

Atovaquone / Proguanil 250/100 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Tegoprazan 50 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

Vonoprazan 20 mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04568772

YYD601 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Nexium 40mgNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

PlacebosNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03943992

Laparoscopic total left-sided surgical approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

Laparoscopic traditional bilateral approachNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07252115

laparoscopic surgeryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01587859

Intravenous FamotidineNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

Oral Maalox/ MylantaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06241183

patients with GERD after LSGNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05416645

Esophageal studiesNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05180253

Endoscopic gastroplicationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00235677

Alginate-antacid groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Non antacid alginate groupNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03516188

Swallowable Sponge Cell Sampling DeviceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02890979

Laparoscopic fundoplication (surgery)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00251927

CKD-381NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

NexiumNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03211143

Tracheal LavageNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00865995

24-hour esophageal pH monitoring using an ambulatory system (Ohmega, MMS, Enschede, The Netherlands).NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04454112

sleeve gastrectomyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

sleeve gastrectomy with omentopexyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04994665

One Anastomosis Gastric Bypass (OAGB)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04422405

ZegeridNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

LosecNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01710995

AG1321001(drug)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00380315

IW-3718NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02030925

Matching PlaceboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02030925

commercially available lansoprazoleNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610

matched placeboNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03015610

SAPIEN Transcatheter Valve ImplantationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00676689

Cognitive Behavioral Therapy (CBT)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06939465

Lifestyle management (sham control)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06939465

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.